In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Aeterna Zentaris (AEZS – Research Report), with a price target of $28.00. The company’s shares closed last Friday at $4.35.
Selvaraju covers the Healthcare sector, focusing on stocks such as Genmab, Aeterna Zentaris, and Regulus. According to TipRanks, Selvaraju has an average return of -31.1% and a 18.39% success rate on recommended stocks.
Currently, the analyst consensus on Aeterna Zentaris is a Moderate Buy with an average price target of $28.00.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $24.38 and a one-year low of $4.12. Currently, Aeterna Zentaris has an average volume of 83.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Æterna Zentaris, Inc. operates as a specialty biopharmaceutical company that is engaged in developing and commercializing novel treatments in oncology, endocrinology and women’s health. It operates through biopharmaceutical segment. AEterna Zentaris was founded on September 12, 1990 and is headquartered in Charleston, SC.
Read More on AEZS:
- Stronghold Digital Mining (SDIG) Has a New Rating from H.C. Wainwright
- Goldman Sachs Remains a Buy on Bayerische Motoren Werke Aktiengesellschaft (BAMXF)
- Melco’s internally designed Morpheus-branded service program awarded by prestigious global accolade “ATD Excellence in Practice Awards 2022”
- AppTech Payments Corp. to Present at the H.C. Wainwright 24th Annual Global Investment Conference
- Targa Resources Corp. to Participate in Investor Conferences
